Samsung Bioepis Co., Ltd. vs. Alexion Pharmaceuticals, Inc. et al.
Explore the PTAB proceeding IPR2023-01070 filed by Samsung Bioepis Co., Ltd. on 2023-06-16. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2023-01070
Filing Date
2023-06-16
Accorded Filing Date
2023-06-16
Institution Decision Date
2023-12-19
Last Modified Date
2024-09-04
Proceeding Type
IPR
Termination Date
2024-09-04
Trial Status
Terminated-Settled
Parties & Counsel
Petitioner
Samsung Bioepis Co., Ltd.
Represented By
Rhyu, Michelleet alPatent Owner / Respondent
Alexion Pharmaceuticals, Inc. et al.
Represented By
Flattmann, Geraldet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Terminated-Settled
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 32343 | Mark Dukes | +1 803-255-9381 |
| 35218 | Craig Killen | +1 704-417-3127 |
| 35561 | Neil Jones | +1 864-250-2260 |
| 37320 | Cynthia Kanik | +1 617-202-4623 |
| 38220 | Anthony Laurentano | +1 617-202-4024 |
| 38872 | Jane Remillard | +1 617-202-4628 |
| 41302 | Susan Jackson | +1 704-417-3126 |
| 41710 | Jeanne Di Giorgio | +1 617-227-7400 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 10,703,809 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 78,307,006 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2009022050 | US Continuation / Sibling | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2007106585 A1 | PCT World Application | View Official Patent → |
| 🇺🇸 United States | US 2012023751 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,718,880 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,725,504 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,732,149 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,590,189 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2020039221 | US Continuation / Sibling | View Official Patent → |
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc. et al.
Amgen Inc. v. Alexion Pharmaceuticals, Inc.
Amgen, Inc. v. Alexion Pharmaceuticals, Inc.
Amgen, Inc. v. Alexion Pharmaceuticals, Inc.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.